2025
WS16.05Impact of elexacaftor/tezacaftor/ivacaftor on glucose tolerance in adolescents with cystic fibrosis. Data from the MODUL-CF study
Bonnel A, Galderisi A, Weiss L, Sermet-Gaudelus I, Besancon A, Letierce A, Sahki D, Group M. WS16.05Impact of elexacaftor/tezacaftor/ivacaftor on glucose tolerance in adolescents with cystic fibrosis. Data from the MODUL-CF study. Journal Of Cystic Fibrosis 2025, 24: s33. DOI: 10.1016/j.jcf.2025.03.586.Peer-Reviewed Original ResearchOral glucose tolerance testAbnormal glucose toleranceNormal glucose toleranceCF-related diabetesBaseline oral glucose tolerance testAbnormal glucose tolerance groupCystic fibrosisGlucose toleranceNormal glucose tolerance groupEffective CFTR modulatorsOGTT glucoseBMI z-scoreYear of treatmentImpaired fasting glucoseImpaired glucose toleranceGlucose tolerance testForced expiratory volumeCFTR modulatorsPulmonary infectionDecrease recurrenceBaseline characteristicsRelated diabetesFasting GlucoseTolerance testInsulin treatmentProphylactic anticoagulant therapy is associated with improved survival in ICU patients with non-COVID-19 pneumonia: a retrospective cohort study
Hu H, Zhu Y, Hu R, Zhao L, Zeng X, Wu X, Qiu R, Nie Y, Sharma L, Chang D. Prophylactic anticoagulant therapy is associated with improved survival in ICU patients with non-COVID-19 pneumonia: a retrospective cohort study. Frontiers In Pharmacology 2025, 16: 1597885. PMID: 40406481, PMCID: PMC12095157, DOI: 10.3389/fphar.2025.1597885.Peer-Reviewed Original ResearchProphylactic anticoagulant therapyShort-term mortalityKaplan-Meier survival analysisAnticoagulant therapyICU patientsPropensity score matchingPulmonary infectionImproved survivalNon-COVID-19Subgroup analysisNon-COVID-19 pneumoniaDuration of anticoagulant therapyAssociated with improved survivalMultivariate Cox regression modelSurvival analysisEffect of anticoagulant therapyMedical Information Mart for Intensive Care IV databaseCox regression analysisRetrospective cohort studyAssociated with reduced short-term mortalityOptimal administration strategiesCox regression modelsPrognostic factorsAnticoagulation groupCoagulation disordersPersonalized inhaled bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis
Chan B, Stanley G, Kortright K, Vill A, Modak M, Ott I, Sun Y, Würstle S, Grun C, Kazmierczak B, Rajagopalan G, Harris Z, Britto C, Stewart J, Talwalkar J, Appell C, Chaudary N, Jagpal S, Jain R, Kanu A, Quon B, Reynolds J, Teneback C, Mai Q, Shabanova V, Turner P, Koff J. Personalized inhaled bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis. Nature Medicine 2025, 31: 1494-1501. PMID: 40301561, PMCID: PMC12092284, DOI: 10.1038/s41591-025-03678-8.Peer-Reviewed Original ResearchConceptsPhage therapyCystic fibrosisEvidence of trade-offsTreated with phagesEvolutionary trade-offClinical impact of antimicrobial resistanceMultidrug-resistant Pseudomonas aeruginosaBacterial virulenceAntimicrobial resistance crisisLytic virusesDecrease antibiotic resistanceSputum microbiomePhageBacteriophage therapyImpact of antimicrobial resistanceAntibiotic resistanceResistance crisisStandard antibioticsAntimicrobial resistanceSputum densityMultidrug resistancePulmonary infectionCompassionate basisClinical courseMedian agePulmonary Infections in People with HIV
Grammatico M, Shenoi S, Lemieux S, Akgün K. Pulmonary Infections in People with HIV. 2025, 793-819. DOI: 10.1007/978-3-031-77335-8_31.Peer-Reviewed Original ResearchP-1503. Dual β-Lactam Approach for Treatment of Mycobacterium abscessus Infections in Adults – Results in 19 Patients
Kalyatanda G, Dousa K, Lyons H, Mardourian M, Rhodes J, Iakovidis A, El-Helou G, Wilson B, Daley C, Holland S, Kreiswirth B, Nguyen D, Shin E, Kurz S, Johnson J, Bonomo R. P-1503. Dual β-Lactam Approach for Treatment of Mycobacterium abscessus Infections in Adults – Results in 19 Patients. Open Forum Infectious Diseases 2025, 12: ofae631.1672. PMCID: PMC11778049, DOI: 10.1093/ofid/ofae631.1672.Peer-Reviewed Original ResearchSubspecies abscessusB-lactamAssociated with high cure ratesIn vitro susceptibility resultsMulti-drug regimensCurrent treatment regimensSolid organ transplantationHigh cure ratesTime to initiationOptimize treatment outcomesMab infectionSynergy testClinical cureImmunocompromised patientsPulmonary infectionDiscontinued treatmentTreatment regimensCase reportClinical outcomesCure rateImmunocompromised individualsAutoimmune diseasesTreatment successEarly treatmentCulture conversion
2024
An unusual case of primary melioidotic prostatic disease: Misdiagnosed as benign prostatic hyperplasia
Cai Y, Jiang H, Li T, Luo D, Li P, Wang Y. An unusual case of primary melioidotic prostatic disease: Misdiagnosed as benign prostatic hyperplasia. Heliyon 2024, 10: e37906. PMID: 39323819, PMCID: PMC11422042, DOI: 10.1016/j.heliyon.2024.e37906.Peer-Reviewed Original ResearchBenign prostatic hyperplasiaProstate diseaseProstatic hyperplasiaBurkholderia pseudomallei</i>.Urine culturePulmonary infectionTrimethoprim-sulfamethoxazoleSurvival rate of patientsTreated with imipenemUrinary tract infectionAnti-infective treatmentRate of patientsHistory of hypertensionYear old maleMultiple organ damageProstatic abscessTract infectionsInflammatory markersClinical manifestationsCure rateUnusual caseFatal infectious diseaseOrgan damageDifficulty urinatingSurvival ratePostinfectious Pulmonary Complications: Establishing Research Priorities to Advance the Field: An Official American Thoracic Society Workshop Report.
Auld S, Sheshadri A, Alexander-Brett J, Aschner Y, Barczak A, Basil M, Cohen K, Dela Cruz C, McGroder C, Restrepo M, Ridge K, Schnapp L, Traber K, Wunderink R, Zhang D, Ziady A, Attia E, Carter J, Chalmers J, Crothers K, Feldman C, Jones B, Kaminski N, Keane J, Lewinsohn D, Metersky M, Mizgerd J, Morris A, Ramirez J, Samarasinghe A, Staitieh B, Stek C, Sun J, Evans S. Postinfectious Pulmonary Complications: Establishing Research Priorities to Advance the Field: An Official American Thoracic Society Workshop Report. Annals Of The American Thoracic Society 2024, 21: 1219-1237. PMID: 39051991, DOI: 10.1513/annalsats.202406-651st.Peer-Reviewed Original ResearchConceptsPulmonary infectionTreatment of pulmonary infectionsLower respiratory tract infectionsLong-term morbidityRespiratory tract infectionsShort-term outcomesAberrant host responseBurden of morbidityReview potential mechanismsPulmonary complicationsTract infectionsPulmonary pathogensSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Causative pathogenRespiratory syndrome coronavirus 2Therapeutic strategiesSyndrome coronavirus 2Host responseInfectionMorbidityPotential mechanismsCoronavirus 2Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis
Murray T, Stanley G, Koff J. Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis. Infectious Disease Clinics Of North America 2024, 38: 149-162. PMID: 38280761, DOI: 10.1016/j.idc.2023.12.002.Peer-Reviewed Original ResearchConceptsMultidrug-resistant organismsCystic fibrosis transmembrane conductance regulatorCystic fibrosisBeta-lactam/beta-lactamase combinationDevelopment of inhaled formulationsMethicillin-resistant Staphylococcus aureusTherapeutic approachesMultidrug-resistant organism infectionSystemic adverse eventsMultidrug-resistant infectionsTransmembrane conductance regulatorRespiratory tract infectionsCystic fibrosis patientsGram-negative organismsInnovative therapeutic approachesPulmonary infectionTract infectionsConductance regulatorBurkholderia sp.Multidrug resistanceAdverse eventsTreatment optionsAntibiotic resistanceFibrosis patientsOptimal doseLung infections due to emerging fungal pathogens
Roman F, Pischel L, Azar M. Lung infections due to emerging fungal pathogens. Current Opinion In Pulmonary Medicine 2024, 30: 258-265. PMID: 38411158, DOI: 10.1097/mcp.0000000000001059.Peer-Reviewed Original ResearchConceptsEndemic mycosesManagement of pulmonary infectionsFungal pathogensPathogenic fungiAntifungal prophylaxisBlastomyces speciesFungal infectionsFungal organismsAspergillus moldsEnvironmental changesImmunocompromised hostsPulmonary infectionTherapeutic challengeLung infectionMycosesClinical evidenceClinical managementIncreased incidencePulmonary diseaseEnlarged poolDisease burdenInfectionLomentosporaScedosporiumDiagnostic capabilities
2023
A Novel Zinc (II) Porphyrin Is Synergistic with PEV2 Bacteriophage against Pseudomonas aeruginosa Infections
Geyer J, Krupa K, Harris Z, Sun Y, Sharma L, Würstle S, Hu B, Stanley G, Rajagopalan G, Pellot E, Koff J, Robinson J. A Novel Zinc (II) Porphyrin Is Synergistic with PEV2 Bacteriophage against Pseudomonas aeruginosa Infections. Antibiotics 2023, 12: 735. PMID: 37107097, PMCID: PMC10135120, DOI: 10.3390/antibiotics12040735.Peer-Reviewed Original ResearchMinimum inhibitory concentrationMinimum bactericidal concentrationCystic fibrosisAntiviral activityPseudomonas aeruginosa infectionLife-threatening infectionsAntibiotic-resistant infectionsDose-dependent responsePulmonary infectionPotent bactericidal activityAeruginosa infectionMouse lungPsA populationImmune systemVivo modelLung cellsPSA cellsHealth concernNovel therapeuticsInfectionLung modelH441 cellsOpportunistic bacterial pathogenSignificant decreaseInhibitory concentration
2022
Pneumocystis jirovecii pneumonia and deep vein thrombosis in a patient with glioblastoma multiforme
Hussain H, Paidas M, Fadel A, Garcia E, Saadoon Z, Mendez L, Jayakumar A. Pneumocystis jirovecii pneumonia and deep vein thrombosis in a patient with glioblastoma multiforme. Discoveries 2022, 10: e161. PMID: 37457643, PMCID: PMC10338259, DOI: 10.15190/d.2022.20.Peer-Reviewed Original ResearchDeep vein thrombosisPneumocystis jirovecii pneumoniaPneumocystis jirovecii pneumonia infectionAcute deep vein thrombosisJirovecii pneumoniaVein thrombosisPneumonia infectionGlioblastoma multiformeBilateral lower extremity swellingGround glass changesLower extremity swellingChest X-rayPolymerase chain reaction testChain reaction testPulmonary infectionExtremity swellingBronchoalveolar lavageClinical featuresInterstitial infiltratesAtypical infectionsEmergency departmentMedical historyFurther managementSulfamethoxazole treatmentDoppler ultrasoundInhaled Bacteriophage Therapy for Multi-Drug Resistant Achromobacter.
Winzig F, Gandhi S, Lee A, Würstle S, Stanley G, Capuano I, Neuringer I, Koff J, Turner P, Chan B. Inhaled Bacteriophage Therapy for Multi-Drug Resistant Achromobacter. The Yale Journal Of Biology And Medicine 2022, 95: 413-427. PMID: 36568830, PMCID: PMC9765334.Peer-Reviewed Original ResearchConceptsCF patientsCystic fibrosisChronic pulmonary infectionGlobal public health threatBacterial lung infectionsChallenging clinical problemPublic health threatChronic bacterial lung infectionsPulmonary infectionRespiratory statusLung infectionClinical problemBacteriophage therapyInfectionAntimicrobial-resistant bacteriaTherapyHealth threatPhage therapyPatientsAMR infectionsResistant bacteriaLytic bacteriophagesPossible benefitsChemical antibioticsCurrent studyNovel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis
Murray T, Stanley G, Koff J. Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis. Clinics In Chest Medicine 2022, 43: 667-676. PMID: 36344073, DOI: 10.1016/j.ccm.2022.06.008.Peer-Reviewed Original ResearchConceptsMultidrug-resistant organismsCystic fibrosisTherapeutic approachesNontuberculous mycobacteriaCystic fibrosis transmembrane conductance regulator (CFTR) dysfunctionSystemic adverse eventsRespiratory tract infectionsMethicillin-resistant Staphylococcus aureusAdditional clinical trialsNew treatment optionsPharmacokinetics/pharmacodynamicsInnovative therapeutic approachesMultidrug-resistant infectionsMDRO infectionAdverse eventsPulmonary infectionTract infectionsOptimal dosingTreatment optionsClinical trialsNew therapiesNegative organismsInfectionAntibiotic resistancePatientsDematiaceous fungal infections in solid organ transplantation: Systematic review and Bayesian meta‐analysis
Radcliffe C, Radcliffe AJ, Azar MM, Grant M. Dematiaceous fungal infections in solid organ transplantation: Systematic review and Bayesian meta‐analysis. Transplant Infectious Disease 2022, 24: e13819. PMID: 35253959, DOI: 10.1111/tid.13819.Peer-Reviewed Original ResearchConceptsSolid organ transplant recipientsDematiaceous fungal infectionSoft tissue infectionsFungal infectionsInfectious syndromesSystematic reviewEarly post-transplant periodCentral nervous system infectionCommon infectious syndromesPost-transplant periodNervous system infectionOrgan transplant recipientsSolid organ transplantationEnglish-language reportsInfection typeKidney recipientsLiver recipientsPediatric reportsTransplant recipientsPulmonary infectionSystem infectionTissue infectionsWorse prognosisDisseminated infectionMean age
2021
Understanding the Host in the Management of Pneumonia. An Official American Thoracic Society Workshop Report
Dela Cruz CS, Evans SE, Restrepo MI, Dean N, Torres A, Amara-Elori I, Awasthi S, Caler E, Cao B, Chalmers JD, Chastre J, Cohen TS, Cohen AH, Crothers K, Di YP, Egan ME, Feldman C, Gautam S, Halstead ES, Herold S, Jones BE, Luna C, Niederman MS, Mendez R, Menendez R, Mizgerd JP, Nusrat R, Ramirez J, Shindo Y, Waterer G, Yeligar SM, Wunderink RG. Understanding the Host in the Management of Pneumonia. An Official American Thoracic Society Workshop Report. Annals Of The American Thoracic Society 2021, 18: 1087-1097. PMID: 34242148, PMCID: PMC8328365, DOI: 10.1513/annalsats.202102-209st.BooksConceptsLung infectionOfficial American Thoracic Society Workshop ReportAmerican Thoracic Society meetingLong-term health outcomesRisk of pneumoniaHost risk factorsManagement of pneumoniaExtremes of ageClinical practice guidelinesTreatment of pneumoniaInnovative trial designsPneumonia pathogenesisCritical illnessPulmonary infectionImmunosuppressive disordersPneumonia therapyOutcome definitionsRisk factorsClinical trialsPractice guidelinesRespiratory diseasePneumoniaPneumonia StudySystemic effectsTrial designDivergent and self-reactive immune responses in the CNS of COVID-19 patients with neurological symptoms
Song E, Bartley CM, Chow RD, Ngo TT, Jiang R, Zamecnik CR, Dandekar R, Loudermilk RP, Dai Y, Liu F, Sunshine S, Liu J, Wu W, Hawes IA, Alvarenga BD, Huynh T, McAlpine L, Rahman NT, Geng B, Chiarella J, Goldman-Israelow B, Vogels CBF, Grubaugh ND, Casanovas-Massana A, Phinney BS, Salemi M, Alexander JR, Gallego JA, Lencz T, Walsh H, Wapniarski AE, Mohanty S, Lucas C, Klein J, Mao T, Oh J, Ring A, Spudich S, Ko AI, Kleinstein SH, Pak J, DeRisi JL, Iwasaki A, Pleasure SJ, Wilson MR, Farhadian SF. Divergent and self-reactive immune responses in the CNS of COVID-19 patients with neurological symptoms. Cell Reports Medicine 2021, 2: 100288. PMID: 33969321, PMCID: PMC8091032, DOI: 10.1016/j.xcrm.2021.100288.Peer-Reviewed Original ResearchNeurological symptomsImmune responseCerebrospinal fluidAnti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodiesCOVID-19Self-reactive immune responsesSARS-CoV-2 antibodiesCompartmentalized immune responseCSF immunoglobulin GRole of autoimmunityCOVID-19 patientsB cell responsesCoronavirus disease 2019Immune surveyNeurologic sequelaePulmonary infectionBrain infectionSerum antibodiesDisease 2019Monoclonal antibody targetsAnimal modelsTarget epitopesCell activationCell responsesSingle-cell RNA sequencing#39: Streptococcus anginosus Group Infections in Children: A Retrospective Cohort Study, 2015–2019
Amin O, Smith O, Berkowitz F, Lyon T, Kao C, Shane A, Yildirim I, Gonzalez M. #39: Streptococcus anginosus Group Infections in Children: A Retrospective Cohort Study, 2015–2019. Journal Of The Pediatric Infectious Diseases Society 2021, 10: s6-s6. DOI: 10.1093/jpids/piaa170.018.Peer-Reviewed Original ResearchStreptococcus anginosus groupSAG infectionsPolymicrobial infectionsUpper respiratory tract infectionRespiratory tract infectionsCentral nervous systemSite of infectionDisease 15Underlying comorbiditiesLaboratory featuresPulmonary infectionRetrospective cohortTract infectionsRetrospective reviewClinical outcomesClinical presentationAbscess formationMedian lengthCombination therapyGenitourinary tractCommon siteNervous systemStreptococcus constellatusAntibiotic susceptibilityPresentation site
2020
Nocardia veterana infections: case report and systematic review
Radcliffe C, Peaper D, Grant M. Nocardia veterana infections: case report and systematic review. New Microbes And New Infections 2020, 39: 100833. PMID: 33456780, PMCID: PMC7797559, DOI: 10.1016/j.nmni.2020.100833.Peer-Reviewed Case Reports and Technical NotesChronic cutaneous graftOral antibiotic therapySoft tissue abscessesHost diseaseCutaneous graftAntibiotic therapyPulmonary infectionCase reportDrainage proceduresEmpirical treatmentCondition warrantsSystematic reviewInfectionOpportunistic pathogenSystematic literature reviewFirst reportLiterature reviewReportAbscessRelapseReviewAzithromycinGraftTherapyNocardiaPulmonary Infections in the Immunocompromised Host
Yildirim I, Gibson J, Danziger-Isakov L. Pulmonary Infections in the Immunocompromised Host. Respiratory Medicine 2020, 235-252. DOI: 10.1007/978-3-030-54924-4_20.Peer-Reviewed Original ResearchPulmonary infectionHematopoietic stem cell transplantationCurrent immune statusSolid organ transplantationStem cell transplantationPrimary immunodeficiency patientsImmunocompromised childrenCommon complicationImmune compromiseImmunocompromised hostPulmonary diseaseBronchoalveolar lavageImaging findingsClinical symptomsCell transplantationImmune statusImmunodeficiency patientsInvasive studiesOrgan transplantationHigh riskCommon pathogensPatientsInfectionExposure historyTransplantationExophiala Dermatitidis Isolated From Blood In Patient With Steroid Use
Yurtsever N, Dougherty P, Condon S, Orsini R, Berman M, Berry G, Duong S. Exophiala Dermatitidis Isolated From Blood In Patient With Steroid Use. American Journal Of Clinical Pathology 2020, 154: s154-s155. PMCID: PMC7665285, DOI: 10.1093/ajcp/aqaa161.337.Peer-Reviewed Original ResearchBlood culturesExophiala dermatitidisAsymptomatic patientsSteroid useFollow-upBeta-D-glucan testHistory of chronic obstructive pulmonary diseaseDiagnose asymptomatic patientsSerum cryptococcus antigenUrinary tract infectionChest X-rayChronic obstructive pulmonary diseaseTreated with doxycyclineState public health laboratoriesE. dermatitidisObstructive pulmonary diseaseIsolates of E. dermatitidisCentral nervous systemPublic health laboratoriesCryptococcus antigenDisseminated diseasePulmonary infectionInvasive infectionsSteroid treatmentTract infections
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply